Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 3/20 | 0.46 |
| ▸ | PPP5C | P53041 | 2/20 | 0.46 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9881386 | 0.80 | PPP5C (0.49) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL9880146 | 0.80 | TFPI2 (0.60) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL9880162 | 0.79 | PPP5C (0.48) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL9880160 | 0.77 | TSHR (0.54) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL12124014 | 0.75 | TFPI2 (0.66) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL13556911 | 0.75 | TFPI2 (0.66) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL16731268 | 0.71 | PPP5C (0.41) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL9880171 | 0.70 | PPP5C (0.39) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL22863835 | 0.69 | PPM1B (0.33) | — | |
| SCHEMBL10050922 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TFPI2 4324/4885PPP5C 2709/4885PPP2CA 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.